Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Bone and Mineral Metabolism
Published in: Journal of Bone and Mineral Metabolism 4/2015

01-07-2015 | Invited Review

Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases

Authors: Danielle A. Callaway, Jean X. Jiang

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2015

Login to get access

Abstract

Osteoclasts are cells derived from bone marrow macrophages and are important in regulating bone resorption during bone homeostasis. Understanding what drives osteoclast differentiation and activity is important when studying diseases characterized by heightened bone resorption relative to formation, such as osteoporosis. In the last decade, studies have indicated that reactive oxygen species (ROS), including superoxide and hydrogen peroxide, are crucial components that regulate the differentiation process of osteoclasts. However, there are still many unanswered questions that remain. This review will examine the mechanisms by which ROS can be produced in osteoclasts as well as how it may affect osteoclast differentiation and activity through its actions on osteoclastogenesis signaling pathways. In addition, the contribution of ROS to the aging-associated disease of osteoporosis will be addressed and how targeting ROS may lead to the development of novel therapeutic treatment options.
Literature
1.
Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y (2009) Oxidative stress in bone remodelling and disease. Trends Mol Med 15:468–477PubMedCrossRef
2.
Vaananen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113:377–381PubMed
3.
Boyle W, Simonet W, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342PubMedCrossRef
4.
Altindag O, Erel O, Soran N, Celik H, Selek S (2008) Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int 28:317–321PubMedCrossRef
5.
Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O’Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2007) Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285–27297PubMedCentralPubMedCrossRef
6.
Muthusami S, Ramachandran H, Muthusamy B, Vasudevan G, Prabhu V, Subramaniam V, Jagadeesan A, Narasimhan S (2005) Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin Chim Acta 360:81–86PubMedCrossRef
7.
Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z (2007) Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem 295:45–52PubMedCrossRef
8.
Bax BE, Alam ASMT, Banerji B, Bax CMR, Bevis PJR, Stevens CR, Moonga BS, Blake DR, Zaidi M (1992) Stimulation of osteoclastic bone-resorption by hydrogen-peroxide. Biochem Biophys Res Commun 183:1153–1158PubMedCrossRef
9.
Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR (1990) Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 85:632–639PubMedCentralPubMedCrossRef
10.
Yalin S, Bagis S, Polat G, Dogruer N, Aksit SC, Hatungil R, Erdogan C (2005) Is there a role of free oxygen radicals in primary male osteoporosis ? Clin Exp Rheumatol 23:689–692PubMed
11.
Harman D (1956) Aging—a theory based on free-radical and radiation-chemistry. J Gerontol 11:298–300PubMedCrossRef
12.
Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82:47–95PubMed
13.
Sareila O, Kelkka T, Pizzolla A, Hultqvist M, Holmdahl R (2011) NOX2 complex-derived ROS as immune regulators. Antioxid Redox Signal 15:2197–2208PubMedCrossRef
14.
Key LL, Ries WL, Taylor RG, Hays BD, Pitzer BL (1990) Oxygen derived free-radicals in osteoclasts—the specificity and location of the nitroblue tetrazolium Reaction. Bone 11:115–119PubMedCrossRef
15.
16.
Steinbeck MJ, Appel WH, Verhoeven AJ, Karnovsky MJ (1994) Nadph-oxidase expression and in-situ production of superoxide by osteoclasts actively resorbing bone. J Cell Biol 126:765–772PubMedCrossRef
17.
Yang S, Ries WL, Key LL (1998) Nicotinamide adenine dinucleotide phosphate oxidase in the formation of superoxide in osteoclasts. Calcif Tissue Int 63:346–350PubMedCrossRef
18.
Darden AG, Ries WL, Wolf WC, Rodriguiz RM, Key LL (1996) Osteoclastic superoxide production and bone resorption: stimulation and inhibition by modulators of NADPH oxidase. J Bone Miner Res 11:671–675PubMedCrossRef
19.
Fraser JH, Helfrich MH, Wallace HM, Ralston SH (1996) Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone 19:223–226PubMedCrossRef
20.
Suda N, Morita I, Kuroda T, Murota SI (1993) Participation of oxidative stress in the process of osteoclast differentiation. Biochim Biophys Acta 1157:318–323PubMedCrossRef
21.
Kim H, Kim IY, Lee SY, Jeong D (2006) Bimodal actions of reactive oxygen species in the differentiation and bone-resorbing functions of osteoclasts. FEBS Lett 580:5661–5665PubMedCrossRef
22.
Hall TJ, Schaeublin M, Jeker H, Fuller K, Chambers TJ (1995) The role of reactive oxygen intermediates in osteoclastic bone-resorption. Biochem Biophys Res Commun 207:280–287PubMedCrossRef
23.
Wong BR, Josien R, Choi Y (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65:715–724PubMed
24.
Ha H, Kwak HB, Lee SW, Jin HM, Kim HM, Kim HH, Lee ZH (2004) Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 301:119–127PubMedCrossRef
25.
Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N, Lee SY (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106:852–859PubMedCrossRef
26.
Bartell S, Kim H, Ambrogini E, Han L, Iyer S, Serra Ucer S, Rabinovitch P, Jilka R, Weinstein R, Zhao H, O’Brien C, Manolagas S, Almeida M (2014) FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun 5:3773PubMedCentralPubMedCrossRef
27.
Lee NK, Choi HK, Kim DK, Lee SY (2006) Rac1 GTPase regulates osteoclast differentiation through TRANCE-induced NF-kappa B activation. Mol Cell Biochem 281:55–61PubMedCrossRef
28.
Wang YQ, Lebowitz D, Sun CX, Thang H, Grynpas MD, Glogauer M (2008) Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. J Bone Miner Res 23:260–270PubMedCrossRef
29.
Sasaki H, Yamamoto H, Tominaga K, Masuda K, Kawai T, Teshima-Kondo S, Rokutan K (2009) NADPH oxidase-derived reactive oxygen species are essential for differentiation of a mouse macrophage cell line (RAW264.7) into osteoclasts. J Med Invest 56:33–41PubMedCrossRef
30.
Sasaki H, Yamamoto H, Tominaga K, Masuda K, Kawai T, Teshima-Kondo S, Matsuno K, Yabe-Nishimura C, Rokutan K (2009) Receptor activator of nuclear factor-kappa B ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues. Free Radic Biol Med 47:189–199PubMedCrossRef
31.
Yang S, Madyastha P, Bingel S, Ries W, Key L (2001) A new superoxide-generating oxidase in murine osteoclasts. J Biol Chem 276:5452–5458PubMedCrossRef
32.
Yang S, Zhang YZ, Ries W, Key L (2004) Expression of Nox4 in osteoclasts. J Cell Biochem 92:238–248PubMedCrossRef
33.
Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG (2006) Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18:69–82PubMedCrossRef
34.
Takac I, Schroder K, Zhang LL, Lardy B, Anilkumar N, Lambeth JD, Shah AM, Morel F, Brandes RP (2011) The e-loop is involved in hydrogen peroxide formation by the nadph oxidase Nox4. J Biol Chem 286:13304–13313PubMedCentralPubMedCrossRef
35.
Case AJ, Li SM, Basu U, Tian J, Zimmerman MC (2013) Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons. Am J Physiol Heart Circ Physiol 305:H19–H28PubMedCentralPubMedCrossRef
36.
37.
Goettsch C, Babelova A, Trummer O, Erben RG, Rauner M, Rammelt S, Weissmann N, Weinberger V, Benkhoff S, Kampschulte M, Obermayer-Pietsch B, Hofbauer LC, Brandes RR, Schroder K (2013) NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Investig 123:4731–4738PubMedCentralPubMedCrossRef
38.
Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202:1261–1269PubMedCentralPubMedCrossRef
39.
Kim MS, Yang YM, Son A, Tian YS, Lee SI, Kang SW, Muallem S, Shin DM (2010) RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem 285:6913–6921PubMedCentralPubMedCrossRef
40.
Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa-B transcription factor and HIV-1. EMBO J 10:2247–2258PubMedCentralPubMed
41.
Decuypere JP, Monaco G, Missiaen L, De Smedt H, Parys JB, Bultynck G (2011) IP(3) receptors, mitochondria, and Ca signaling: implications for aging. J Aging Res 2011:920178PubMedCentralPubMedCrossRef
42.
Rizzuto R, Brini M, Murgia M, Pozzan T (1993) Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science 262:744–747PubMedCrossRef
43.
Figueira TR, Barros MH, Camargo AA, Castilho RF, Ferreira JCB, Kowaltowski AJ, Sluse FE, Souza-Pinto NC, Vercesi AE (2013) Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. Antioxid Redox Signal 18:2029–2074PubMedCrossRef
44.
McCormack JG, Halestrap AP, Denton RM (1990) Role of calcium-ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70:391–425PubMed
45.
Srinivasan S, Koenigstein A, Joseph J, Sun L, Kalyanaraman B, Zaidi M, Avadhani NG (2010) Role of mitochondrial reactive oxygen species in osteoclast differentiation. Skelet Biol Med 1192:245–252
46.
Zhou J, Ye S, Fujiwara T, Manolagas SC, Zhao H (2013) Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation. J Biol Chem 288:30064–30074PubMedCentralPubMedCrossRef
47.
Ishii KA, Fumoto T, Iwai K, Takeshita S, Ito M, Shimohata N, Aburatani H, Taketani S, Lelliott CJ, Vidal-Puig A, Ikeda K (2009) Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15:259–266PubMedCrossRef
48.
Kanzaki H, Shinohara F, Kajiya M, Kodama T (2013) The Keap1/Nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling. J Biol Chem 288:23009–23020PubMedCentralPubMedCrossRef
49.
Hyeon S, Lee H, Yang Y, Jeong W (2013) Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation. Free Radic Biol Med 65:789–799PubMedCrossRef
50.
Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, Polak JM, MacIntyre I (1995) Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA 92:2954–2958PubMedCentralPubMedCrossRef
51.
Mancini L, Moradi-Bidhendi N, Brandi ML, MacIntyre I (1998) Nitric oxide superoxide and peroxynitrite modulate osteoclast activity. Biochem Biophys Res Commun 243:785–790PubMedCrossRef
52.
53.
Lowik CW, Nibbering PH, van de Ruit M, Papapoulos SE (1994) Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest 93:1465–1472PubMedCentralPubMedCrossRef
54.
Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N (1995) Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res 10:1040–1049PubMedCrossRef
55.
Nilforoushan D, Gramoun A, Glogauer M, Manolson MF (2009) Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion. Nitric Oxide 21:27–36PubMedCrossRef
56.
Baek KH, Oh KW, Lee WY, Lee SS, Kim MK, Kwon HS, Rhee EJ, Han JH, Song KH, Cha BY, Lee KW, Kang MI (2010) Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures. Calcif Tissue Int 87:226–235PubMedCrossRef
57.
Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ (2005) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146:728–735PubMedCrossRef
58.
Deyhim F, Stoecker BJ, Brusewitz GH, Devareddy L, Arjmandi BH (2005) Dried plum reverses bone loss in an osteopenic rat model of osteoporosis. Menopause 12:755–762PubMedCrossRef
59.
Franklin M, Bu SY, Lerner MR, Lancaster EA, Bellmer D, Marlow D, Lightfoot SA, Arjmandi BH, Brackett DJ, Lucas EA, Smith BJ (2006) Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. Bone 39:1331–1342PubMedCrossRef
60.
Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, Zeng WS, Cheng BL, Luo SQ (2005) Reactive oxygen species stimulates receptor activator of NF-kappa B ligand expression in osteoblast. J Biol Chem 280:17497–17506PubMedCrossRef
61.
Bu SY, Lerner M, Stoecker BJ, Boldrin E, Brackett DJ, Lucas EA, Smith BJ (2008) Dried plum polyphenols inhibit osteoclastogenesis by downregulating NFATc1 and inflammatory mediators. Calcif Tissue Int 82:475–488PubMedCrossRef
62.
Moon HJ, Kim SE, Yun YP, Hwang YS, Bang JB, Park JH, Kwon IK (2011) Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp Mol Med 43:605–612PubMedCentralPubMedCrossRef
63.
Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su KG, Kim HH (2006) Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic Biol Med 40:1483–1493PubMedCrossRef
64.
Koh JM, Lee YS, Byun CH, Chang EJ, Kim H, Kim YH, Kim HH, Kim GS (2005) Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. J Endocrinol 185:401–413PubMedCrossRef
65.
Polat B, Halici Z, Cadirci E, Albayrak A, Karakus E, Bayir Y, Bilen H, Sahin A, Yuksel TN (2013) The effect of alpha-lipoic acid in ovariectomy and inflammation-mediated osteoporosis on the skeletal status of rat bone. Eur J Pharmacol 718:469–474PubMedCrossRef
66.
Lever JH (2002) Paget’s disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone 31:434–436PubMedCrossRef
67.
Szymczyk KH, Kerr BAE, Freeman TA, Adams CS, Steinbeck MJ (2006) Involvement of hydrogen peroxide in the differentiation and apoptosis of preosteoclastic cells exposed to arsenite. Biochem Pharmacol 72:761–769PubMedCrossRef
68.
Xiao XH, Liao EY, Zhou HD, Dai RC, Yuan LQ, Wu XP (2005) Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro. J Endocrinol Invest 28:253–260PubMedCrossRef
69.
Le Nihouannen D, Barralet JE, Fong JE, Komarova SV (2010) Ascorbic acid accelerates osteoclast formation and death. Bone 46:1336–1343PubMedCrossRef
70.
Sanbe T, Tomofuji T, Ekuni D, Azuma T, Irie K, Tamaki N, Yamamoto T, Morita M (2009) Vitamin C intake inhibits serum lipid peroxidation and osteoclast differentiation on alveolar bone in rats fed on a high-cholesterol diet. Arch Oral Biol 54:235–240PubMedCrossRef
71.
Kim MH, Ryu SY, Bae MA, Choi JS, Min YK, Kim SH (2008) Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem Toxicol 46:3375–3382PubMedCrossRef
72.
Moon HJ, Ko WK, Han SW, Kim DS, Hwang YS, Park HK, Kwon IK (2012) Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun 418:247–253PubMedCrossRef
73.
Léotoing L, Wauquier F, Guicheux J, Miot-Noirault E, Wittrant Y, Coxam V (2013) The polyphenol fisetin protects bone by repressing NF-kappa B and MKP-1-dependent signaling pathways in osteoclasts. Plos One 8:e68388PubMedCentralPubMedCrossRef
74.
Sakai E, Shimada-Sugawara M, Yamaguchi Y, Sakamoto H, Fumimoto R, Fukuma Y, Nishishita K, Okamoto K, Tsukuba T (2013) Fisetin inhibits osteoclastogenesis through prevention of RANKL-induced ROS production by Nrf2-mediated up-regulation of phase II antioxidant enzymes. J Pharmacol Sci 121:288–298PubMedCrossRef
75.
76.
Li DZ, Zhang QX, Dong XX, Li HD, Ma X (2013) Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells. J Bone Miner Metab 32:494–504PubMedCrossRef
77.
Kondo H, Togari A (2011) Continuous treatment with a low-dose beta-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88:23–32PubMedCrossRef
78.
Kondo H, Takeuchi S, Togari A (2013) beta-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species. Am J Physiol Endocrinol Metab 304:E507–E515PubMedCrossRef
79.
Rao LG, Krishnadev N, Banasikowska K, Rao AV (2003) Lycopene I–effect on osteoclasts: lycopene inhibits basal and parathyroid hormone-stimulated osteoclast formation and mineral resorption mediated by reactive oxygen species in rat bone marrow cultures. J Med Food 6:69–78PubMedCrossRef
80.
Arshad A, Sengupta S, Sharma S, Ghosh R, Sawlani V, Singh MM (2004) In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator. J Steroid Biochem Mol Biol 91:67–78PubMedCrossRef
81.
Kharkwal G, Chandra V, Fatima I, Dwivedi A (2012) Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells. J Mol Endocrinol 48:261–270PubMedCrossRef
82.
Nomura M, Yoshimura Y, Kikuiri T, Hasegawa T, Taniguchi Y, Deyama Y, Koshiro K, Sano H, Suzuki K, Inoue N (2011) Platinum nanoparticles suppress osteoclastogenesis through scavenging of reactive oxygen species produced in RAW264.7 cells. J Pharmacol Sci 117:243–252PubMedCrossRef
83.
Oka Y, Iwai S, Amano H, Irie Y, Yatomi K, Ryu K, Yamada S, Inagaki K, Oguchi K (2012) Tea polyphenols inhibit rat osteoclast formation and differentiation. J Pharmacol Sci 118:55–64PubMedCrossRef
84.
He X, Andersson G, Lindgren U, Li Y (2010) Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun 401:356–362PubMedCrossRef
85.
Kyung TW, Lee JE, Shin HH, Choi HS (2008) Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-alpha by inhibiting activation of NF-kappa B. Exp Mol Med 40:52–58PubMedCentralPubMedCrossRef
86.
Horcajada-Molteni MN, Crespy V, Coxam V, Davicco MJ, Remesy C, Barlet JP (2000) Rutin inhibits ovariectomy-induced osteopenia in rats. J Bone Miner Res 15:2251–2258PubMedCrossRef
87.
Kim MH, Ryu SY, Choi JS, Min YK, Kim SH (2009) Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. J Cell Physiol 221:618–628PubMedCrossRef
88.
Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH (2007) Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem Pharmacol 74:911–923PubMedCrossRef
89.
Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB (2008) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappa B ligand through modulation of NF-kappa B pathway. Int J Cancer 123:1733–1740PubMedCrossRef
90.
Hie M, Tsukamoto I (2011) Administration of zinc inhibits osteoclastogenesis through the suppression of RANK expression in bone. Eur J Pharmacol 668:140–146PubMedCrossRef
Metadata
Title
Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases
Authors
Danielle A. Callaway
Jean X. Jiang
Publication date
01-07-2015
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2015
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-015-0656-4

Other articles of this Issue 4/2015

Journal of Bone and Mineral Metabolism 4/2015 Go to the issue

Original Article

Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice

Original Article

Gender- and body-site-specific factors associated with bone mineral density in a non-institutionalized Korean population aged ≥50 years

Original Article

Efficacy and safety of odanacatib treatment for patients with osteoporosis: a meta-analysis

Original Article

Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study

Original Article

A comparison of the in vitro mineralisation and dentinogenic potential of mesenchymal stem cells derived from adipose tissue, bone marrow and dental pulp

Rapid Communication

Histology of a Harris line in a human distal tibia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits